Physician profile
Y Khalid Siddiq
NPI 1023085081
$2,922.00
in general payments reported to CMS, 2019-2025
29 companies · $673 in 2025
The $673 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $242 · 2022: $282 · 2023: $411 · 2024: $819 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,903.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $513.36 | 2019-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $485.25 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $385.90 | 2019-2025 | Tepezza, Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $192.92 | 2022-2024 | |
| Medtronic, INC. | $181.87 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $158.45 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $101.01 | 2023-2024 | Gvoke Hypopen |
| Beta Bionics, INC. | $95.00 | 2024 | Ilet Bionic Pancreas |
| Becton, Dickinson and Company | $90.97 | 2019 | |
| Mannkind Corporation | $82.91 | 2019-2024 | |
| Sequel Med Tech, LLC | $79.96 | 2025 | Twiist |
| Recordati_rare_diseases_inc. | $64.80 | 2024-2025 | Isturisa, Signifor Lar |
| Ibsa Pharma INC. | $59.25 | 2019-2023 | Tirosint, Licart |
| Dexcom, INC. | $45.36 | 2022-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $43.84 | 2023-2024 | Synthroid |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $37.00 | 2025 | Cequr Simplicity |
| Antares Pharma, INC. | $36.87 | 2019-2020 | |
| Medtronic Minimed, INC. | $35.61 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $32.88 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $26.17 | 2025 | Yorvipath |
| Madrigal Pharmaceuticals | $24.65 | 2025 | Rezdiffra |
| Horizon Therapeutics Plc | $23.93 | 2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $23.40 | 2025 | |
| Lilly USA, LLC | $19.58 | 2022 | |
| Esperion Therapeutics, INC. | $18.74 | 2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.37 | 2022 | |
| Tandem Diabetes Care, INC. | $16.57 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Nalpropion Pharmaceuticals LLC | $16.43 | 2019 | |
| Merck Sharp & Dohme LLC | $11.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Y Siddiq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.